The FTC and Illumina’s Grail: The Tipline for 23 August 2021
Antitrust is not usually a matter of life and death, but administrative law judge D Michael Chappell is going to hear otherwise this week. Starting today, Federal Trade Commission staff will square off with Illumina over the DNA-sequencing company’s completed acquisition of Grail, which is developing an innovative cancer-screening test. Both the government and the merging parties are expected to argue that their opponent is trying to obstruct this life-saving technology.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10